MA33102B1 - Derivatives of 6- (6-o-cycloalkyl or 6-nh-cycloalkyl-triiazolopridzine-sulfanil) (benzothiazole and benzimidazole: preparation and use as a drug and use as inhibitors met - Google Patents

Derivatives of 6- (6-o-cycloalkyl or 6-nh-cycloalkyl-triiazolopridzine-sulfanil) (benzothiazole and benzimidazole: preparation and use as a drug and use as inhibitors met

Info

Publication number
MA33102B1
MA33102B1 MA34147A MA34147A MA33102B1 MA 33102 B1 MA33102 B1 MA 33102B1 MA 34147 A MA34147 A MA 34147A MA 34147 A MA34147 A MA 34147A MA 33102 B1 MA33102 B1 MA 33102B1
Authority
MA
Morocco
Prior art keywords
cycloalkyl
inhibitors
met
triiazolopridzine
sulfanil
Prior art date
Application number
MA34147A
Other languages
Arabic (ar)
French (fr)
Inventor
Dominique Damour
Eric Bacque
Conception Nemecek
Antonio Ugolini
Sylvie Wentzler
Baptiste Ronan
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33102B1 publication Critical patent/MA33102B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

L'INVENTION CONCERNE LES NOUVEAUX PRODUITS DE FORMULE (I) DANS LAQUELLE - - - - REPRÉSENTE UNE LIAISON SIMPLE OU DOUBLE; RA REPRÉSENTE -O-CYCLOALKYLE OU -NH-CYCLOALKYLE; X REPRÉSENTE S, SO OU SO2, A REPRÉSENTE NH OU S; W REPRÉSENTE H, ALKYLE OU COR AVEC R REPRÉSENTE CYCLOALKYLE; ALKYLE; ALCOXY; O-PHÉNYLE; -O-(CH2)N-PHÉNYLE AVEC N= 1 À 4; OU NR1 R2 AVEC R1 REPRÉSENTE H OU ALK ET R2 REPRÉSENTE H, CYCLOALKYLE, HÉTÉROCYCLOALKYLE, OU ALKYLE; OU BIEN R1, R2 FORMENT AVEC N UN CYCLE RENFERMANT ÉVENTUELLEMENT O, S, N ET/OU NH; TOUS CES RADICAUX ÉTANT ÉVENTUELLEMENT SUBSTITUÉS; CES PRODUITS ÉTANT SOUS TOUTES LES FORMES ISOMÈRES ET LES SELS, À TITRE DE MÉDICAMENTS NOTAMMENT COMME INHIBITEURS DE MET.The invention relates to the novel products of formula (I) in which - - - - represents a simple or double bond; RA REPRESENTS -O-CYCLOALKYL OR -NH-CYCLOALKYL; X REPRESENTS S, SO OR SO2, REPRESENTS NH OR S; W REPRESENTS H, ALKYL OR COR WITH R REPRESENT CYCLOALKYL; Alkyl; ALCOXY; O-phenyl; -O- (CH 2) N-phenyl with N = 1 to 4; OR NR1 R2 WITH R1 REPRESENTS H OR ALK AND R2 REPRESENTS H, CYCLOALKYL, HETEROCYCLOALKYL, OR ALKYL; OR R1, R2 FORMULA WITH N A CYCLE INCLUDING O, S, N AND / OR NH; ALL THESE RADICALS ARE POSSIBLY SUBSTITUTED; THESE PRODUCTS ARE IN ALL ISOMERIC FORMS AND SALTS, AS MEDICINES IN PARTICULAR AS MET INHIBITORS.

MA34147A 2009-02-06 2010-02-04 Derivatives of 6- (6-o-cycloalkyl or 6-nh-cycloalkyl-triiazolopridzine-sulfanil) (benzothiazole and benzimidazole: preparation and use as a drug and use as inhibitors met MA33102B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0900510A FR2941949B1 (en) 2009-02-06 2009-02-06 DERIVATIVES OF 6- (6-O-CYCLOALKYL OR 6-NH-CYCLOALKYL-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS INHIBITORS OF MET.
PCT/FR2010/050177 WO2010089506A1 (en) 2009-02-06 2010-02-04 Derivatives of 6-(6-o-cycloalkyl or 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors

Publications (1)

Publication Number Publication Date
MA33102B1 true MA33102B1 (en) 2012-03-01

Family

ID=40863635

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34147A MA33102B1 (en) 2009-02-06 2010-02-04 Derivatives of 6- (6-o-cycloalkyl or 6-nh-cycloalkyl-triiazolopridzine-sulfanil) (benzothiazole and benzimidazole: preparation and use as a drug and use as inhibitors met

Country Status (18)

Country Link
EP (1) EP2393790A1 (en)
JP (1) JP2012517407A (en)
KR (1) KR20110126660A (en)
CN (1) CN102388029A (en)
AR (1) AR075248A1 (en)
AU (1) AU2010212231A1 (en)
BR (1) BRPI1011354A2 (en)
CA (1) CA2751525A1 (en)
CO (1) CO6400222A2 (en)
EA (1) EA201171010A1 (en)
FR (1) FR2941949B1 (en)
IL (1) IL214407A0 (en)
MA (1) MA33102B1 (en)
MX (1) MX2011008312A (en)
SG (1) SG173558A1 (en)
TW (1) TW201040187A (en)
UY (1) UY32419A (en)
WO (1) WO2010089506A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2691650T3 (en) 2011-09-15 2018-11-28 Novartis Ag 3- (quinolin-6-yl-thio) - [1,2,4] -triazolo- [4,3-a] -pyridines 6-substituted as inhibitors of tyrosine kinase c-Met

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
CN101360748B (en) * 2005-11-30 2012-05-30 沃泰克斯药物股份有限公司 Inhibitors of c-met and uses thereof
NZ568666A (en) * 2005-11-30 2011-09-30 Vertex Pharma [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met
ME02736B (en) * 2005-12-21 2017-10-20 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
CA2651979A1 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
PE20121506A1 (en) * 2006-07-14 2012-11-26 Amgen Inc TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS
WO2008051808A2 (en) * 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
PA8792501A1 (en) * 2007-08-09 2009-04-23 Sanofi Aventis NEW DERIVATIVES OF 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL AND BENCIMIDAZOL, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICATIONS, PHARMACEUTICAL COMPOSITIONS AND NEW MAIN USE AS MET INHIBITORS.

Also Published As

Publication number Publication date
AU2010212231A1 (en) 2011-08-25
IL214407A0 (en) 2011-09-27
SG173558A1 (en) 2011-09-29
BRPI1011354A2 (en) 2019-09-24
JP2012517407A (en) 2012-08-02
UY32419A (en) 2010-09-30
EP2393790A1 (en) 2011-12-14
FR2941949B1 (en) 2011-04-01
CA2751525A1 (en) 2010-08-12
EA201171010A1 (en) 2012-03-30
TW201040187A (en) 2010-11-16
WO2010089506A1 (en) 2010-08-12
MX2011008312A (en) 2011-11-02
CN102388029A (en) 2012-03-21
KR20110126660A (en) 2011-11-23
AR075248A1 (en) 2011-03-16
FR2941949A1 (en) 2010-08-13
CO6400222A2 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
MA31685B1 (en) NOVEL 6-TRIAZOLOPYRIDAZINE-SULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS
ATE517882T1 (en) QUINOLINE DERIVATIVES
BRPI0810524B8 (en) (aza)indole derivative, xanthine oxidase inhibitor and pharmaceutical composition comprising said derivative
EA200870193A1 (en) CYTOTOXIC AGENTS, INCLUDING NEW TOMAMYCIN DERIVATIVES, AND THEIR THERAPEUTIC APPLICATION
EA200700096A1 (en) DERIVATIVES 2-CARBAMID-4-PHENYL THIAZOLE, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATION IN THERAPY
EP1679309A4 (en) Antistress drug and medical use thereof
NO20060195L (en) Quinolylamide derivatives as CCR-5 antagonists
GT200600134A (en) NEW COMPOUNDS OF AMINOSULPHONYL DERIVATIVES
UY30498A1 (en) NEW CLASS OF BENZIMIDAZOLILO COMPOUNDS, ITS SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
EA201071370A1 (en) SERO-CONTAINING HETEROCYCLIC DERIVATIVES, HAVING ACTIVITY OF THE BETA SECRETASE INHIBITOR
EA200870302A1 (en) 1,3-DIOXANKARBONIC ACIDS
CR20110031A (en) NEW IMIDAZO DERIVATIVES [1,2-a] PYRIMIDINE, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NEW USE IN PARTICULARLY AS MET INHIBITORS
NO20091025L (en) Arylsulfonamides with analgesic action
NO20070445L (en) Pyrimidine.
NO20083058L (en) Cyclohexylsulfonamide derivatives with H3 receptor activity
NO20076425L (en) Methods of Treating Drug-Resistant Cancer
EA200901423A1 (en) BENZIMIDAZOLY AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
BRPI0714885B8 (en) therapeutic compounds and their use
MA33384B1 (en) Heterocyclic sulfonamides, their uses and the pharmaceutical compositions they contain
NO20083708L (en) 4-Phenyl-thiazole-5-carboxylic acid and 4-phenyl-thiazole-5-carboxylmides as PLK1 inhibitors
BRPI0905687A2 (en) "compound of formula i or i ', pharmaceutical composition, method of treating a patient with a disease, use of the compound"
EA200901474A1 (en) SALTS [4- (6-FLUOR-7-METYLAMINO-2,4-DIOXO-1,4-DIHYDRO-PLAIN-2-CHINAZOLIN-3-IL) -5-CHLORTHIOPHEN-2-ILSULPHONYLMOCHEVANIUM IN VARIOUS CRYSTAL-HEADPHONE-2-ILSULPHONYLMOCHEVAN IN VARIOUS CRYSTAL-4-ILSULPHONYLMOCHEVAN IN VARIOUS CRYSTAL-4-ILSULPHONYLMOCHEVANIUM ON THEIR BASIS
DE602005010744D1 (en) PIPERAZINYLPYRIDINE DERIVATIVES AS AGENTS AGAINST ADIPOSITAS
MA33501B1 (en) New derivatives (6-oxo-1,6-dihydro-pyridine-2 -yl) - amide, their preparation and pharmaceutical use as akt phosphorylation inhibitors (pkb)
ATE466007T1 (en) 5-SUBSTITUTED INDOLE-2-CARBONIC ACID AMIDE DERIVATIVES